EFFECT OF BEVACIZUMAB SUBCONJUNCTIVAL INJECTIONS ON CORNEAL NEWVESSELS - BECONNEC

CHU de Limoges0 个研究点目标入组 42 人开始时间: 2011年5月19日最近更新: 2019年12月10日

适应症

试验速览

暂无简介。

•Patients with corneal neovascularization whatever the origin
•Patient did not receive treatment with topical corticosteroids during the month preceding inclusion.
•Patient who has been properly informed and signed consent
•Patient aged over 18
•Patient affiliated with a health insurance plan or benefit of such a regime
•- Negative pregnancy test for Women at inclusion
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 22

•Patients who received local or general treatment of concomitant prostaglandin derivatives
•Patients with current infection of the cornea or other tissue / organ
•Women of childbearing age without contraception
•Pregnancy and Lactation
•Patient participating in another study
•Patient with contact lenses
•Patients with uncontrolled hypertension
•Patient with a history of stroke, myocardial infarction, angina pectoris, thrombophlebitis, Raynaud's phenomenon.
•Patients hypersensitive to the active substance or any excipients
•Patients hypersensitive to products of Chinese hamster ovary cells or other recombinant human or humanized antibodies.
•Patients with active bacterial eye infections, fungal, parasitic or viral infection (with the exeption of herpes)

发起方

CHU de Limoges